UY39054A - CONTROLLED RELEASE COMPOSITION - Google Patents

CONTROLLED RELEASE COMPOSITION

Info

Publication number
UY39054A
UY39054A UY0001039054A UY39054A UY39054A UY 39054 A UY39054 A UY 39054A UY 0001039054 A UY0001039054 A UY 0001039054A UY 39054 A UY39054 A UY 39054A UY 39054 A UY39054 A UY 39054A
Authority
UY
Uruguay
Prior art keywords
controlled release
release composition
blood concentration
maintain
prevent
Prior art date
Application number
UY0001039054A
Other languages
Spanish (es)
Inventor
Shoji Furuta
Hiroki Wakamori
Naoto Hattori
Chihiro Ishida
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Publication of UY39054A publication Critical patent/UY39054A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Medicinal Preparation (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Es un objeto de la presente invención el de proporcionar una composición de liberación controlada que pueda prevenir un aumento repentino en la concentración en sangre de un ingrediente activo y pueda mantener la concentración en sangre durante un tiempo prolongadoIt is an object of the present invention to provide a controlled release composition that can prevent a sudden increase in the blood concentration of an active ingredient and can maintain the blood concentration for a long time.

UY0001039054A 2020-01-31 2021-01-29 CONTROLLED RELEASE COMPOSITION UY39054A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2020014880 2020-01-31

Publications (1)

Publication Number Publication Date
UY39054A true UY39054A (en) 2021-07-30

Family

ID=77079418

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039054A UY39054A (en) 2020-01-31 2021-01-29 CONTROLLED RELEASE COMPOSITION

Country Status (4)

Country Link
AR (1) AR121207A1 (en)
TW (1) TW202140010A (en)
UY (1) UY39054A (en)
WO (1) WO2021153716A1 (en)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100355130B1 (en) * 1992-09-18 2003-01-30 야마노우치세이야쿠 가부시키가이샤 Hydrogel Sustained Release Tablet
TWI478712B (en) * 2008-09-30 2015-04-01 Astellas Pharma Inc Pharmaceutical composition for modified release
GB201400412D0 (en) * 2014-01-10 2014-02-26 Heart Biotech Ltd Pharmaceutical formulations for the treatment of pulmonary arterial hypertension
WO2017042731A1 (en) * 2015-09-10 2017-03-16 Lupin Limited Amorphous form of selexipag and solid dispersion thereof
EP3192502A1 (en) * 2016-01-15 2017-07-19 Sandoz Ag Pharmaceutical composition of selexipag
EP3335699A1 (en) * 2016-12-15 2018-06-20 H e x a l Aktiengesellschaft Selexipag formulation in liquisolid system
AR113882A1 (en) * 2017-11-16 2020-06-24 Nippon Shinyaku Co Ltd CONTROLLED RELEASE PREPARATION
US20240024311A1 (en) * 2019-02-03 2024-01-25 Jayendrakumar Dasharathlal Patel A controlled release pharmaceutical composition of selexipag or it's active metabolite
EP3705115B1 (en) * 2019-03-07 2021-06-30 Alfred E. Tiefenbacher (GmbH & Co. KG) Composition containing selexipag
WO2020255157A1 (en) * 2019-06-20 2020-12-24 Aizant Drug Research Solutions Private Limited Stable solid dosage form of selexipag and process for preparation thereof

Also Published As

Publication number Publication date
AR121207A1 (en) 2022-04-27
WO2021153716A1 (en) 2021-08-05
TW202140010A (en) 2021-11-01

Similar Documents

Publication Publication Date Title
CL2019000406A1 (en) Diacylglycerol acyltransferase 2 inhibitors.
CL2015001984A1 (en) (divisional sol. 1567-2013) combinations of active ingredients comprising pyridylethylbenzamides and other active ingredients.
BR112015022433A2 (en) drug permeable drug delivery devices and methods
NI201400120A (en) DIACILGLICEROL ACILTRANSFERASE 2 INHIBITORS
CR20130356A (en) DEVICES AND METHODS FOR WOUND OR SKIN TREATMENT
CO2018013925A2 (en) Anaerobic blood storage and pathogen inactivation method
CL2020003074A1 (en) Inhibitors of the integrated stress response pathway.
AR098586A1 (en) TWO-PART OXIDIZING SYSTEM FOR COMPOSITIONS FOR ORAL CARE
AR101581A1 (en) COLUTORY COMPOSITION
CL2018003067A1 (en) Formulations and methods for the treatment of photosynthetic organisms and improve the qualities and quantities of yields with formulations composed of glycans
UY39054A (en) CONTROLLED RELEASE COMPOSITION
ECSP15003613A (en) TRANSDERMAL FORMULATION CONTAINING COX INHIBITORS
PE20110283A1 (en) COMPOSITION CONTAINING NIFURTIMOX
GT200900296A (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF AN NON-STEROID ANTI-INFLAMMATORY AGENT AND AN ANTI-CONVULSIVE AGENT.
BR112022020136A2 (en) ANTIBODY FORMULATION
CL2020000551A1 (en) Formulation for topical use for the control and prevention of parasites in animals.
EA201391085A1 (en) CHEMICAL COMPOSITION WITH HYDROGEN PEROXIDE AND NANO-EMULSION OF LONG-SECONDARY ALCOHOLS
CO2021004612A2 (en) 4-pyrazin-2-ylmethyl-morpholine derivatives and their use as a medicine
CO2020007892A2 (en) Use of functionalized calcium carbonate as active ingredient
AR104184A1 (en) PESTICIDE COMPOSITION THAT INCLUDES METOMILO AND LUFENURON
BR102020012866A8 (en) TOPICAL COMPOSITIONS CONTAINING N-ACYL-DIPEPTIDE AND GLYCOLIC ACID DERIVATIVES
CL2015001788A1 (en) Pest Control Agent
CO2021000763A2 (en) Stability of vitamin d in b-hydroxy-b-methylbutyrate (hmb)
AR110957A1 (en) ORAL THERAPEUTIC AGENT FOR THYROID
CY1124264T1 (en) FROM THYROID ORAL THERAPEUTIC AGENT